Can a simple blood test predict cancer treatment success?

NCT ID NCT04892849

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This observational study is collecting blood samples and medical images from 200 people with several types of solid tumors (like lung, head and neck, and esophageal cancers) who are receiving immunotherapy and radiation as part of their standard care. Researchers want to see if changes in immune cells in the blood or patterns in scans can predict how well the treatment works or if side effects occur. The goal is to find reliable markers that could guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could identify blood or imaging markers that help predict which patients benefit most from combining immunotherapy with radiation.
What could go wrong
This is an observational study, not testing a new treatment. It may not find reliable biomarkers, and results may not apply to all patients or cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Radiation Oncology, Universitätsklinikum Erlangen

    RECRUITING

    Erlangen, Bavaria, 91054, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.